Ebsteins anomaly of the tricuspid valve medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:


==Overview==
==Overview==
Medical management of patients with ebstein’s anomaly consists of giving supportive care, controlling heart rhythm with antiarrhythmic drugs, inotropic agents and diuretics for heart failure and anticoagulant in patients with history of atrial fibrillation and paradoxical embolus.
Medical management of patients with Ebstein’s anomaly consists of supportive care such as: *Control of the heart rhythm with antiarrhythmic drugs
*Inotropic agents and [[diuretics]] for [[heart failure]]
*Anticoagulation in patients with [[atrial fibrillation]] and [[paradoxical embolization]]
 
==Medical Therapy==
==Medical Therapy==



Revision as of 21:24, 20 October 2012

Ebsteins anomaly of the tricuspid valve Microchapters

Home

Patient Information

Overview

Historical Perpective

Classification

Pathophysiology

Causes

Differentiating Ebstein's Anomaly from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography

CT

MRI

Other Imaging Findings

Other diagnostic studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Ebsteins anomaly of the tricuspid valve medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ebsteins anomaly of the tricuspid valve medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ebsteins anomaly of the tricuspid valve medical therapy

CDC on Ebsteins anomaly of the tricuspid valve medical therapy

Ebsteins anomaly of the tricuspid valve medical therapy in the news

Blogs on Ebsteins anomaly of the tricuspid valve medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Ebsteins anomaly of the tricuspid valve medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] and Claudia P. Hochberg, M.D. [2]Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [3]

Overview

Medical management of patients with Ebstein’s anomaly consists of supportive care such as: *Control of the heart rhythm with antiarrhythmic drugs

Medical Therapy

ACC / AHA 2008 Guidelines- Recommendation for Medical Therapy- Ebstein's Anomaly of the Tricuspid Valve(DO NOT EDIT)[1]

Class I
"1.Anticoagulation with warfarin is recommended for patients with Ebstein’s anomaly with a history of paradoxical embolus or atrial fibrillation. (Level of Evidence: B) "

Ebstein's cardiophysiology typically presents as an (antidromic) AV nodal reentrant tachycardia with associated pre-excitation. In this setting, the preferred pharmacological treatment agent is procainamide. Since AV-blockade may promote conduction over the accessory pathway, drugs like beta blockers, calcium channel blockers and digoxin are contraindicated.

If there is atrial fibrillation with pre-excitation, treatment options include procainamide, flecainide, propafenone, dofetilide and ibutilide since these medications slow conduction in the accessory pathway causing the tachycardia and should be administered before considering electrical cardioversion. Intravenous amiodarone may also convert atrial fibrillation and/or slow the ventricular response.

Warfarin is recommended for patients with Ebstein’s anomaly with a history of paradoxical embolus or atrial fibrillation.

Diuretics aid in flushing excess fluid from the body, thereby easing strain on the heart.

Cardiac glycosides are used to maintain proper heart rhythm while increasing the strength of each contraction.

References

  1. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.


Template:WH

Template:WS